Document:

Filed by Bowne Pure Compliance

Exhibit 10.1

TERMINATION AGREEMENT

THIS TERMINATION AGREEMENT (this “Agreement”) is made as of June 30, 2008 (the “Effective Date”), by and among
QUEPASA CORPORATION, a Nevada corporation (together with its subsidiaries, “Quepasa”), MEXICANS & AMERICANS THINKING
TOGETHER FOUNDATION, INC., a Delaware not-for-profit corporation (“MATTF”), and MEXICANS & AMERICANS TRADING TOGETHER,
INC., a Delaware corporation (“MATT”) (each a “Party” and collectively the “Parties”).

WHEREAS, the Parties are parties to that certain Corporate Sponsorship and Management Services Agreement dated as
of November 20, 2006 (the “Services Agreement”);

WHEREAS, pursuant to the Services Agreement, Quepasa owes MATTF the sum of $7,556,052 (the “Indebtedness”);

WHEREAS, Quepasa desires to issue to MATTF, and MATTF desires to accept from Quepasa, preferred stock of Quepasa
in consideration for MATTF’s cancellation of the Indebtedness, upon the terms and subject to the conditions set forth
herein;

WHEREAS, the Parties hereby agree to waive all rights granted to them under the Services Agreement and to
terminate the Services Agreement in its entirety, subject to the terms and conditions of this Agreement, including the
survival of the Surviving Provisions (defined below);

NOW, THEREFORE, in consideration of the mutual covenants contained in this Agreement and for other good and
valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties hereby agree as follows:

1. Agreement to Sell and Purchase. Quepasa hereby issues, transfers, sells, assigns, grants and conveys
to MATTF and MATTF agrees to accept and purchase from Quepasa, 25,000 shares of Series A Preferred Stock, par value
$0.001 per share, of Quepasa (the “Preferred Stock”) in exchange for the Parties termination of the Services Agreement
(other than the Survival Provisions), cancellation of the Indebtedness, and the waiver and releases set forth herein in
accordance with the terms and subject to the conditions set forth in this Agreement. The Preferred Stock has the
rights and preferences set forth in the certificate of designation attached hereto as Exhibit A (the “Certificate of
Designation”) and shall have the registration rights set forth on the form registration rights agreement attached
hereto as Exhibit B (the “Registration Rights Agreement” and together with the Certificate of Designation, the
“Ancillary Documents”).

 

1

 

2. Termination of the Services Agreement. Any and all rights granted to the Parties pursuant to the
Services Agreement shall be terminated, any post-termination rights or obligations which would otherwise survive
termination are hereby terminated and the Services Agreement is hereby terminated, null and void and of no effect
whatsoever; provided that Sections 2.3(b), 2.3(c), 2.3(d), 6, 8.3(d), 8.3(e), 13 and 15 of the Services Agreement shall
survive such termination and the Parties shall continue to have the rights and obligations under such Sections (such
Sections collectively, the “Surviving Provisions”). The Parties hereby consent to the termination of the Services
Agreement as provided herein.

3. Waiver of Rights under the Services Agreement. The Parties hereby waive any and all rights granted to,
or accrued by, them pursuant to the Services Agreement, other than the rights under the Surviving Provisions.

4. Releases.

(a) MATT and MATTF, in consideration of good and valuable consideration received and to be received from Quepasa
hereunder, the sufficiency of which is acknowledged, each releases and discharges Quepasa, its subsidiaries and
affiliates and its and their respective officers, directors, shareholders, employees, agents, attorneys and affiliates
and its and their respective heirs, personal representatives, successors and assigns (collectively, the “Quepasa
Releasees”), of and from all claims, demands, causes of action, suits, actions, proceedings, judgments, debts, damages,
liabilities and obligations, at law, equity or otherwise, which MATT or MATTF or any of its affiliates and any of their
respective successors or assigns had, have or may hereafter have against the Quepasa Releasees arising under the
Services Agreement from the beginning of the world to the Effective Date other than the claims, demands, causes of
action, suits, actions, proceedings, judgments, debts, damages and liabilities arising the Surviving Provisions; except
that, MATT and MATTF in no way release or discharge Quepasa’s obligations under this Agreement or the Ancillary
Documents. Nothing herein shall be construed as an admission by Quepasa that MATT or MATTF has any claim against it.
MATT and MATTF and their respective successors and assigns, further waive any and all manner of notice, knowledge or
discovery of any and all such actual or alleged claims of cause of action.

(b) Quepasa, in consideration of good and valuable consideration received and to be received from MATT and MATTF
hereunder, the sufficiency of which is acknowledged, releases and discharges MATT and MATTF and its and their
subsidiaries and affiliates and its and their respective officers, directors, shareholders, employees, agents,
attorneys and affiliates and its and their respective heirs, personal representatives, successors and assigns
(together, the “MATT/MATTF Releasees”), of and from all claims, demands, causes of action, suits, actions, proceedings,
judgments, debts, damages, liabilities and obligations, at law, equity or otherwise, which Quepasa or any of its
affiliates and any of their respective successors or assigns had, have or may hereafter have against the MATT/MATTF
Releasees arising under the Services Agreement from the beginning of the world to the Effective Date other than the
claims, demands, causes of action, suits, actions, proceedings, judgments, debts, damages and liabilities arising under
the Surviving Provisions; except that, Quepasa in no way releases or discharges MATT’s or MATTF’s obligations under
this Agreement or the Ancillary Agreements. Nothing herein shall be construed as an admission by MATT or MATTF that
Quepasa has any claim against it or them. Quepasa, its affiliates and their respective successors and assigns, further
waive any and all manner of notice, knowledge or discovery of any and all such actual or alleged claims of cause of
action.

 

2

 

5. Representations and Warranties of Quepasa. Quepasa hereby represents and warrants that the following
statements are true and correct as of the Effective Date and hereby acknowledges and confirms that MATT and MATTF are
relying on such representations and warranties in connection with entering into this Agreement and the Registration
Rights Agreement:

(a) Organization of Quepasa. Quepasa is a corporation duly organized, validly existing, and in good
standing under the laws of the State of Nevada and has all requisite corporate power and authority to carry on its
business as presently conducted. Quepasa is duly qualified to transact business and is in good standing in each
jurisdiction in which the failure to so qualify would have a Material Adverse Effect. For purposes of this Agreement,
“Material Adverse Effect” means a material adverse effect on the business, property, liabilities, condition (financial
or otherwise), assets, operations or results of operations of Quepasa, taken as a whole, including (i) any event that
may reasonably cause the delisting of trading of the Quepasa’s common stock on the Nasdaq Stock Market and (ii) the
existence, threat or facts that could give rise to any Securities and Exchange Commission investigation relating to
Quepasa.

(b) Authorization of Transaction. Quepasa has the requisite corporate power and authority to execute and
deliver this Agreement and the Ancillary Documents, to perform its obligations hereunder and thereunder and to
consummate the transactions contemplated hereby and thereby. The execution and delivery of this Agreement and the
Ancillary Documents and the consummation of the transactions contemplated hereby and thereby, including the
authorization, issuance, sale and delivery of the Preferred Stock and the common stock issuable upon conversion
thereof, have been duly authorized by all necessary corporate action on the part of Quepasa and its directors and
stockholders. This Agreement and the Ancillary Documents have been duly executed and delivered by Quepasa and
constitute the valid and legally binding obligations of Quepasa, enforceable in accordance with its and their terms and
conditions.

(c) Noncontravention; Consents. Neither the execution and the delivery of this Agreement nor any of the
Ancillary Documents, nor the consummation of the transactions contemplated hereby and thereby, will (with or without
notice or the lapse of time) (i) violate any constitution, statute, regulation, rule, injunction, judgment, order,
decree, ruling, charge, or other restriction of any government, governmental agency, or court to which Quepasa is
subject or any provision of the charter or bylaws of Quepasa, (ii) violate any applicable rule, regulation or
interpretative memorandum of any applicable national securities exchange (including the Nasdaq Stock Market), or (iii)
conflict with, result in a breach of, constitute a default under, result in the acceleration of, create in any party
the right to accelerate, terminate, modify, or cancel any obligation under, result in the loss of a benefit under, or
require any notice under any agreement, contract, lease, license, instrument, or other arrangement to which Quepasa is
a party or by which it is bound or to which any of its assets is subject or result in the imposition of any security
interest upon any of its assets, except where the conflict, breach, default, acceleration, termination, modification,
cancellation, loss, failure to give notice, or security interest would not have a Material Adverse Effect on Quepasa or
on the ability of the Parties to consummate the transactions contemplated by this Agreement. No consent, approval,
order or authorization of, or registration, declaration or filing with, any government, governmental agency, court or
national securities exchange (including the Nasdaq Stock Market) is required by or with respect to Quepasa in
connection with the execution and delivery of this Agreement or any of the Ancillary Documents or the consummation of
the transactions contemplated hereby and thereby, including the authorization, issuance, sale and delivery of the
Preferred Stock and the common stock issuable upon conversion thereof.

 

3

 

(d) Capitalization. The authorized capital stock of Quepasa consists of 50,000,000 shares of common
stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, 25,000 of which have been designated Series
A Preferred Stock. There are no shares of preferred stock of Quepasa outstanding, except the Preferred Stock to be
issued at Closing. There are no outstanding obligations, rights or agreements entitling any person, firm or corporation
or other entity to acquire shares of preferred stock of Quepasa or any equity security of Quepasa having any preference
or priority as to dividends, redemption or distribution of assets on liquidation, merger or otherwise which is superior
to or on parity with any such preference or priority of the Preferred Stock. The Preferred Stock has the powers,
designations, preferences, limitations, restrictions and rights set forth in the Certificate of Designation.

(e) Valid Issuance of Shares. The Preferred Stock, when issued and delivered in accordance with the terms
set forth in this Agreement, will be validly issued, fully paid and nonassessable and free of restrictions on transfer
other than restrictions on transfer under the Registration Rights Agreement, applicable state and federal securities
laws, and liens or encumbrances created by or imposed by MATTF. Assuming the accuracy of the representations of MATTF
in Section 6, the offer, sale and issuance of the Preferred Stock as contemplated by this Agreement will be issued in
compliance with all applicable federal and state securities laws. The Common Stock issuable on conversion of the
Preferred Stock has been duly authorized, validly reserved for issuance, and upon issuance in accordance with the terms
of the Certificate of Designation, will be validly issued, fully paid, and nonassessable, and free of restrictions on
transfer other than restrictions on transfer under applicable federal and state securities laws, and liens or
encumbrances created by or imposed by MATTF. Based in part on the representations of MATTF in Section 6, the common
stock issuable on conversion of the Preferred Stock will be issued in compliance with all applicable federal and state
securities laws.

(f) Brokers’ Fees. Quepasa has no liability or obligation to pay any fees or commissions to any broker,
finder, or agent with respect to the transactions contemplated by this Agreement for which MATTF could become liable or
obligated.

(g) SEC Reports. Quepasa has timely filed with the Securities and Exchange Commission (“SEC”) all
reports, schedules, forms, statements and other documents (including exhibits as either filed or deemed filed by
incorporation by reference and any other information incorporated by reference) required to be filed by it since
January 1, 2008. As of their respective filing dates, Quepasa’s Annual Report on Form 10-KSB for its fiscal year ended
December 31, 2007 and each statement or report filed by Quepasa with the SEC on or after the date of filing by Quepasa
of such Annual Report on Form 10-KSB pursuant to the Securities Exchange Act of 1934, as amended, (the “Exchange Act”)
(collectively, the “SEC Documents”) complied in all material respects with the requirements of the Exchange Act and the
published rules and regulations of the SEC, and none of the SEC Documents contained (at the time they were filed or if
amended or superseded by a filing then on the date of such filing) any untrue statement of a material fact or omitted
to state a material fact necessary to make the statements made therein, in light of the circumstances in which they
were made, not misleading.

 

4

 

(h) Financial Statements. Quepasa has filed with the SEC the following financial statements of Quepasa,
which are included in the SEC Documents: (i) audited balance sheets, income statements, statements of shareholders’
equity and statement of cash flows as of and for the fiscal years ended December 31, 2007 and 2006; and (ii) unaudited
balance sheets, income statements and cash flow statements as of and for the three months ended March 31, 2008
(collectively, including the notes thereto, the “Financial Statements”). The Financial Statements were complete and
correct in all material respects as of their respective dates, complied in form in all material respects with
applicable accounting requirements and with the rules and regulations of the SEC with respect thereto as of their
respective dates, and have been prepared in accordance with generally accepted accounting principles in the United
States (“GAAP”) applied on a consistent basis throughout the periods indicated and consistent with each other, except
that the unaudited Financial Statements may not contain all footnotes required by GAAP (none of which will be material)
and except the financial statements for the fiscal year ended December 31, 2006 which were subsequently restated, to
the extent of that restatement. The Financial Statements present fairly the financial condition and operating results
of Quepasa as of the dates and during the periods indicated, subject in the case of the unaudited financial statements
to normal year-end audit adjustments (none of which will be material).

(i) Changes. Since March 31, 2008, there has not been any change, event or condition of any character,
whether or not in the ordinary course of business, whether separately or in the aggregate with other changes, events or
conditions, that could reasonably be expected to result in a Material Adverse Effect.

(j) Legal Compliance. Quepasa has complied with all applicable laws (including rules, regulations, codes,
plans, injunctions, judgments, orders, decrees, rulings, and charges thereunder) of federal, state, local, and foreign
governments, except where the failure to comply would not have a Material Adverse Effect.

(k) Tax Matters. Quepasa has filed all required income tax returns and paid all required income taxes,
except where the failure to file income tax returns or to pay income taxes would not have a Material Adverse Effect.
Quepasa has not applied for or been provided any extension of time to file any tax return. No claim has ever been made
by an authority in a jurisdiction where Quepasa does not file tax returns that it is or may be subject to taxation by
that jurisdiction. There are no security interests on any of the assets of Quepasa that arose in connection with any
failure, or alleged failure, to pay any tax. Quepasa has withheld and paid all required taxes in connection with
amounts paid or owing to any employee, independent contractor, creditor, stockholder or other third party.

(l) Litigation. There is no claim, action, suit, proceeding, arbitration, complaint, charge or
investigation pending or, to Quepasa’s knowledge, currently threatened against Quepasa, or any officer, director, or
employee of Quepasa, which would reasonably be expected to have a Material Adverse Effect, and to Quepasa’s knowledge,
there is not any reasonable basis therefore.

 

5

 

(m) Insolvency. No insolvency proceedings of any character, including without limitation, bankruptcy,
receivership, reorganization, composition or arrangement with creditors, voluntary or involuntary, designating Quepasa
as bankrupt or insolvent, are pending or, to the knowledge of Quepasa threatened, and Quepasa has not made an
assignment for the benefit of creditors, nor have they taken any action with a view to, or which would constitute the
basis for, the institution of any such insolvency proceedings.

(n) Registration Rights. Except (i) as set forth in the Registration Rights Agreement, (ii) that certain
registration rights agreement with Mexicans & Americans Trading Together, Inc. dated as of October 17, 2006 and (iii)
that certain registration rights agreement with Richard L. Scott Investments, LLC and F. Stephen Allen dated as of
March 21, 2006, Quepasa is presently not under any obligation and has not granted any rights to register under the
Securities Act any of its presently outstanding securities or any of its securities that may hereafter be issued.

(o) Disclaimer of Other Representations and Warranties. Quepasa shall not be deemed to have made to MATTF
or MATT any representations or warranties other than those expressly made in this Section 5.

6. Representations and Warranties of MATT and MATTF. Each of MATT and MATTF hereby severally represents
and warrants with respect to itself and not with respect to the other, that the following statements are true and
correct as of the Effective Date and each hereby acknowledges and confirms that Quepasa is relying on representations
and warranties made by such Party in this Section 6 in connection with entering into this Agreement and in the case of
the representations and warranties by MATTF the Registration Rights Agreement:

(a) Organization of MATT and MATTF. It is a corporation duly organized, validly existing, and in good
standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its
business as presently conducted.

(b) Authorization of Transaction. It has the requisite corporate power and authority to execute and
deliver this Agreement and the Registration Rights Agreement and to perform its obligations hereunder and thereunder
and to consummate the transactions contemplated hereby and thereby. The execution and delivery of this Agreement and
the Registration Rights Agreement and the consummation of the transactions contemplated hereby and thereby have been
duly authorized by all necessary corporate action on the part of and its directors and stockholders. This Agreement
and the Registration Rights Agreement have been duly executed and delivered by MATT or MATTF, as applicable, and
constitute the valid and legally binding obligation of MATT or MATTF, as applicable, enforceable in accordance with
their terms and conditions.

 

6

 

(c) Noncontravention. Neither the execution and the delivery of this Agreement nor the Registration Rights
Agreement, nor the consummation of the transactions contemplated hereby and thereby, will (with or without notice or
the lapse of time) (i) violate any constitution, statute, regulation, rule, injunction, judgment, order, decree,
ruling, charge, or other restriction of any government, governmental agency, or court to which MATT or MATTF, as
applicable, is subject or any provision of the charter or bylaws of MATT or MATTF, as applicable, or (ii) conflict
with, result in a breach of, constitute a default under, result in the acceleration of, create in any party the right
to accelerate, terminate, modify, or cancel, or require any notice under any agreement, contract, lease, license,
instrument, or other arrangement to which MATT or MATTF, as applicable, is a party or by which it is bound or to which
any of its assets is subject or result in the imposition of any security interest upon any of its assets, except where
the conflict, breach, default, acceleration, termination, modification, cancellation, failure to give notice, or
security interest would not have a material adverse effect on MATT or MATTF, as applicable, or on the ability of the
Parties to consummate the transactions contemplated by this Agreement.

(d) Brokers’ Fees. It does not have any liability or obligation to pay any fees or commissions to any
broker, finder, or agent with respect to the transactions contemplated by this Agreement for which Quepasa could become
liable or obligated.

(e) Insolvency. No insolvency proceedings of any character, including without limitation, bankruptcy,
receivership, reorganization, composition or arrangement with creditors, voluntary or involuntary, designating MATT or
MATTF, as applicable, as bankrupt or insolvent, are pending or, to the knowledge of MATT or MATTF, as applicable,
threatened, and MATT or MATTF, as applicable, has not made an assignment for the benefit of creditors, nor has it taken
any action with a view to, or which would constitute the basis for, the institution of any such insolvency proceedings.

(f) Investment Representations. MATTF represents and acknowledges the following:

(i) MATTF acknowledges it is purchasing the securities comprising the Preferred Stock for investment and has no
present intent to sell such securities, has no need for liquidity in such investment, has made commitments to
investments that are not readily marketable which are reasonable in relation to the undersigned’s net worth and can
afford a complete loss of such investment.

(ii) MATTF is not relying on Quepasa with respect to the tax and other economic considerations of an investment in
the securities comprising the Preferred Stock, and MATTF has relied on the advice of, or has consulted with, only
MATTF’s own advisors.

(iii) MATTF is not subscribing for the securities comprising the Preferred Stock as a result of or subsequent to
any advertisement, articles, notice or other communication published in any newspaper, television or radio or presented
at any seminar or meeting, or any solicitation of a subscription by a person not previously known to the undersigned in
connection with investments in securities generally.

 

7

 

(iv) The representations, warranties and agreements of MATTF contained herein shall survive the execution and
delivery of this Agreement and the purchase of the Preferred Stock.

(g) Disclaimer of Other Representations and Warranties. Neither MATT nor MATTF shall be deemed to have
made to Quepasa any representations or warranties other than those expressly made by MATT or MATTF, as applicable, in
this Section 6.

7. Closing Deliveries. Simultaneously with the execution and delivery of this Agreement, the Parties are
delivering the following documents:

(a) Quepasa. Quepasa is delivering to MATTF:

	 	(i)	 	An original stock certificate evidencing the Preferred
Stock;

	 	(ii)	 	The Certificate of Designation filed with and certified by
the Secretary of State of the State of Nevada; and

	 	(iii)	 	An original executed Registration Rights Agreement.

(b) MATTF. MATTF is delivering to Quepasa an original executed Registration Rights Agreement.

8. Additional Documents. The Parties agree to execute and delivery such additional instruments as may be
reasonably required by another Party, in order to carry out the purpose and intent of this Agreement and to fulfill the
obligations of the Parties hereunder.

9. Entire Agreement. This Agreement sets forth the entire understanding of the Parties with respect to
its subject matter, merges and supersedes any prior or contemporaneous understandings with respect to its subject
matter, and shall not be modified or terminated except by a written instrument executed by Quepasa and MATT and/or
MATTF (to extent such Party is effected by such amendment).

10. Severability. If any provision of this Agreement is held to be invalid or unenforceable by any court
or tribunal of competent jurisdiction, the remainder of this Agreement shall not be affected by such judgment, and such
provision shall be carried out as nearly as possible according to its original terms and intent to eliminate such
invalidity or unenforceability.

11. Successors and Assigns. This Agreement shall inure to the benefit of, be binding on and be
enforceable by, the parties and their respective successors and assigns.

 

8

 

12. Communications. All notices, consents and other communications given under this Agreement shall be in
writing and shall be deemed to have been duly given (a) when delivered by hand or by FedEx or a similar overnight
courier to, (b) five days after being deposited in any United States post office enclosed in a postage prepaid
registered or certified envelope addressed to, or (c) when successfully transmitted by fax (with a confirming copy of
such communication to be sent as provided in (a) or (b) above) to, the party for whom intended, at the address or fax
number for such party set forth below, or to such other address or fax number as may be furnished by such party by
notice in the manner provided herein; provided, however, that any notice of change of address or fax number shall be
effective only on receipt.

	 	 	 
	If to Quepasa:

	 	If to MATT:
	 	 	 
	
 
	 	Mexicans & Americans
	Quepasa Corporation

	 	Trading Together, Inc.
	224 Datura Street, Suite 1100

	 	7550 IH 10 West, Suite 630
	West Palm Beach, FL 33401

	 	San Antonio, TX 78229
	Attention: Attn: Michael D. Matte

	 	Attn: Andres Gonzalez Saravia
	 	 	 
	
 
	 	If to MATTF:
	 	 	 
	
 
	 	Mexicans & Americans Thinking
Together Foundation, Inc.
	
 
	 	329 Old Guilbeau Street
	
 
	 	San Antonio, TX 78204
	
 
	 	Attn: Andres Gonzalez Saravia

13. Construction; Counterparts. The headings contained in this Agreement are for convenience only and
shall in no way restrict or otherwise affect the construction of the provisions hereof. References in this Agreement
to Sections are to the sections of this Agreement. This Agreement may be executed in multiple counterparts, each of
which shall be an original and all of which together shall constitute one and the same instrument.

14. Attorneys’ Fees. In the event that there is any controversy or claim arising out of or relating to
this Agreement, or to the interpretation, breach or enforcement thereof, and any action or proceeding is commenced to
enforce the provisions of this Agreement, the prevailing party shall be entitled to reasonable attorneys’ fees, costs
and expenses (including such fees and costs on appeal).

15. Governing Law. This Agreement shall be governed by the laws of the State of New York applicable to
agreements made and fully to be performed in such state, without giving effect to conflicts of law principles; provided
that matters of corporate law shall be governed by the laws of the State of Nevada applicable to agreements made and
fully to be performed in such state, without giving effect to conflicts of law principles.

[Signatures on Next Page]

 

9

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date.

QUEPASA CORPORATION

By:                                                                              

Name:                                                                         

Title:                                                                          

MEXICANS & AMERICANS

TRADING TOGETHER, INC.

By:                                                                              

Name:                                                                         

Title:                                                                          

MEXICANS & AMERICANS THINKING

TOGETHER FOUNDATION, INC.

By:                                                                              

Name:                                                                         

Title:                                                                          

 

10

 

EXHIBIT A

CERTIFICATE OF DESIGNATION

 

11

 

EXHIBIT B

FORM REGISTRATION RIGHTS AGREEMENT

 

12Filed by Bowne Pure Compliance

Exhibit 10.1

Confidential treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as [  *  ].
A complete version of this exhibit has been filed separately with the Securities and Exchange
Commission.

SUPPLY AGREEMENT

THIS SUPPLY AGREEMENT (this “Agreement”) is made effective as of the date of the last signature on
the Agreement (“Effective Date”), by and between TomoTherapy Incorporated, a Wisconsin corporation
with its principal address at 1240 Deming Way, Madison, WI 53717, USA (“TomoTherapy”), and Hitachi
Medical Corporation, a Japanese corporation with its principal address at 4-14-1 Soto-Kanda,
Chiyoda-ku, Tokyo 101-0021, Japan (“Hitachi”).

RECITALS

A. TomoTherapy manufactures and sells the TomoTherapy® Hi ·Art® treatment system, which includes
hardware, software, other equipment and related services (the “Products”).

B. Hitachi manufactures Xenon gas detectors identified by model number CT-WD-5E, rev NA (the
“Detectors”).

C. TomoTherapy desires to purchase the Detectors from Hitachi in order to incorporate them into the
Products which will be distributed by TomoTherapy directly or indirectly on a worldwide basis.

NOW, THEREFORE, for mutual consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties agree as follows:

1.0 SUPPLY OF DETECTORS

1.1 Orders.

A. Purchase Order. Subject to the terms and conditions herein, Hitachi agrees to supply and
deliver to TomoTherapy in non-exclusive basis, and TomoTherapy agrees to purchase from Hitachi, the
Detectors by purchase orders (“Purchase Orders”) that TomoTherapy shall send to Hitachi. Purchase
Orders shall contain, among other things, Purchase Order number and date, quantification of
Detectors ordered, the TomoTherapy Part Number, price per unit, requested delivery dates and
delivery instructions and destination. Purchase Orders shall be issued at least 90 days before the
requested shipment date.

B. Order Acknowledgment. Within five (5) working days of its receipt of a Purchase Order,
Hitachi shall either send written acceptance of the Purchase Order to TomoTherapy or written notice
that the shipment may be delayed, with a revised schedule for delivery.

C. Forecasts. Following execution of this Agreement, TomoTherapy shall provide Hitachi with a
forecast of the Detectors TomoTherapy plans to purchase from Hitachi for the initial twelve (12)
months following the Effective Date (the “Initial Forecast”) and shall provide Hitachi with an
update of such forecast periodically every month for the following six (6) months thereafter
(collectively with the Initial Forecast, the “Forecasts”). The Forecasts are for planning purposes
only, and TomoTherapy shall not be bound to make the planned purchases included in the Forecasts.
TomoTherapy will commit to purchase the number of Detectors specified in the first three (3) months
of each Forecast via the submission of one or more Purchase Orders for the detectors to be
delivered in those three (3) months.

D. Minimum Purchase. TomoTherapy agrees to purchase at least [ * ] Detectors in every six
months period starting with April 1 and October 1 (“Minimum Purchase Quantity”) from Hitachi. In
the event that TomoTherapy fails to purchase Minimum Purchase Quantity, it shall be deemed to be a material breach of this Agreement by TomoTherapy and Hitachi shall have the rights specified
under Article 6 of this Agreement.

 

 

 

E. Capacity. Hitachi agrees that no Purchase Order from TomoTherapy shall go unfilled for
reason of lack of capacity of Hitachi to fulfill such Purchase Order so long as the Purchase Order
requests delivery of a quantity that is no more than the guaranteed number of detectors available
for any given month according to the schedule below. For any Renewal Term, as defined in Section
6.1 herein, the capacity shall be discussed and determined by the parties at that time. Should
TomoTherapy request more detectors in the Purchase Order than Capacity, the parties will discuss at
that time the feasibility of Hitachi filling such an order, and the TomoTherapy forecast for future
order quantities. The previous language not withstanding, the quantity limits discussed in this
Section 1.1E shall not apply in the case of a Last Time Buy, as defined in Section 6.2.

	 	 	 
	Date	 	Guaranteed Capacity
	 
	 	 
	From the Effective Date through [ * ]

	 	[ * ] detectors per month
	 
	 	 
	From [ * ] through [ * ]

	 	[ * ] detectors per month
	 
	 	 
	From [ * ] through the expiration of the contract

	 	[ * ] detectors per month

F. Pricing and Payment of Invoices. The price for each Detector during the Term of this
Agreement is Japanese Yen [ * ]on FOB Japan basis. The parties agree that the pricing structure
will be renegotiated annually upon the anniversary date of this Agreement, taking into
consideration pricing adjustments due to increases or decreases in raw materials, internal
production costs, and the estimated units needed by TomoTherapy during the impending Forecasts.
TomoTherapy shall pay all invoices issued under this Agreement in Japanese Yen by telegraphic
transfer through banks within 45 days from the date of invoice. All bank charges incurred by
TomoTherapy shall be born by TomoTherapy.

G. Delivery Terms. Delivery terms for the Detectors are FOB Japan. Title and risk of loss of
the Detectors transfers from Hitachi to TomoTherapy at the point of FOB Japan.

H. Non-Conforming Detectors. In the event of a discrepancy concerning the quality and/or
quantity of Detectors ordered, and it appears that such discrepancy was caused by negligence or
other conduct on the part of Hitachi or on the part of an individual or entity under Hitachi’s
control, or if the Detectors received by TomoTherapy do not otherwise conform to that ordered for
whatever reason, TomoTherapy may reject all or a portion of the Detectors so received
notwithstanding any prior payment by TomoTherapy for such Detectors. The Detectors shall be
considered to conform to TomoTherapy’s expectations if they meet the specifications described in
Appendix A hereto. TomoTherapy may require Hitachi to (i) refund funds paid by TomoTherapy for the
non-conforming Detectors, (ii) replace such non-conforming Detectors with conforming Detectors at
Hitachi’s sole cost, or (iii) effect any other remedy as the parties may agree. The choice of
remedies (i) through (iii) contained in the immediately foregoing sentence shall be upon mutual
agreement of the parties.

I. Rejection. The Detectors deemed rejected by TomoTherapy will be reported to Hitachi (and
returned to Hitachi upon their request and at their cost) with a Notice of rejection containing the
reasons for and documentation supporting the rejection. Within fourteen (14) days from Hitachi’s
acceptance of notice of rejection, Hitachi will supply replacement product at no additional cost.

 

2

 

1.2 Technical Information and Support

A. Technical Information. Hitachi shall provide TomoTherapy with technical information and
technical support regarding the Detectors to be reasonably considered necessary for the intended use of the Detectors. Such Technical Information may include but is not necessarily
limited to the Procurement Specification attached hereto as Appendix A. The parties agree that
should TomoTherapy require significant time or resources from Hitachi with respect to the provision
of technical information under the terms of this section, Hitachi shall have the ability to ask for
reasonable NRE as compensation. The terms and conditions of such NRE compensation will be
negotiated by the parties in good faith.

1.3 Quality and Specifications for Performance and Packaging.

A. Specifications and Certifications. Unless otherwise agreed by the parties in writing, the
Detectors sold to TomoTherapy shall conform to the performance specifications set forth in Appendix
A. With each shipment, Hitachi shall provide TomoTherapy with a certification and corresponding
test data demonstrating that the Detectors in that shipment meet or exceed the performance
specifications set forth in Appendix A.

B. Notifications of Changes or Substitutions to Detectors. Hitachi shall provide TomoTherapy
with as much advanced written notice as possible of any change to the form or function of the
Detectors, but under no circumstances shall Hitachi provide TomoTherapy with less than six (6)
months prior notice. Hitachi must obtain TomoTherapy’s prior written consent before making any
material change that might in any way affect quality of performance of the Detectors, including but
not limited to any change in raw material or component, or change in the source of such raw
material or component.

C. Quality Control and Quality Assurance. Hitachi shall maintain its certification under ISO
9001 or an equivalent auditable quality program with comparable requirements during the term of
this Agreement. Hitachi shall maintain a documented process database. Hitachi shall forward its
quality control and quality assurance reports from time to time to TomoTherapy upon TomoTherapy’s
request. TomoTherapy may at any time, with reasonable prior notice to Hitachi, conduct an audit
of Hitachi’s quality control, quality assurance and manufacturing records and processes. If
TomoTherapy identifies any material deficiency during an audit or otherwise, Hitachi will be
required to respond with a corrective action plan to any such findings as soon as possible, and
will provide TomoTherapy with weekly updates as to the progress of such corrective action plan.

D. Customer Complaints or Problems. TomoTherapy agrees to notify Hitachi of all material
customer complaints or problems regarding the Detectors. If TomoTherapy determines that changes to
the design, process, components, materials, assembly or workmanship are beneficial or required to
correct a quality or reliability deficiency, the parties shall, upon notification of such
circumstance, immediately initiate discussions to resolve the problem as soon as possible.
Responses to requests for failure investigation and corrective action shall be performed as soon as
possible with Hitachi providing weekly updates to TomoTherapy on the status of the investigation
and resolution.

E. Detectors Packaging. Detectors to be shipped by Hitachi to TomoTherapy shall be packaged
according to the packaging requirements included in the Procurement Specification attached as
Appendix A hereto.

F. Warranty. Hitachi represents and warrants that the Detectors shall be free from defects in
design, process, components, materials, assembly and workmanship, that the Detectors meet the
performance specifications set forth in Exhibit A,. Any Detector that does not meet the terms of
this warranty during either the first eighteen (18) months after such Detector is shipped by
Hitachi by FOB Japan basis or during the first twelve (12) months after the TomoTherapy Product
that includes the Detector was shipped from TomoTherapy to a TomoTherapy customer, whichever is
earlier, may, at Hitachi’s option, be returned to Hitachi for a full refund or replaced by Hitachi.
Either of the above options shall be at Hitachi’s sole expense. Notwithstanding the foregoing,
TomoTherapy understands and accepts that the Detectors may not meet the Specifications in exposure
of high-energy (Mega Voltage) radiation which is beyond the energy level (Kilo Voltage) of
diagnostic X-ray CT systems, which is not in the scope of Hitachi warranty. HITACHI DOES NOT MAKE
AND HEREBY DISCLAIMS ANY WARRANTY IN REPSECT OF THE DETECTORS OTHER THAN AS PROVIDED ABOVE IN THIS ARTICLE, WHETHER EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF
MERCHANTABILITY OR FITNESS FOR ANY PURPOSE.

 

3

 

1.4 Widespread Failure. For the purposes of this Agreement, “Widespread Failure” means one or
more related defects in the design, material, or workmanship of the Detectors for which Hitachi is
solely responsible, and which (a) are substantially similar in nature or origin, (b) materially
affect the Detector’s safety or efficacy, and (c) are found in fifteen (15) percent of the
installed base of Detectors within any twelve (12) months period during the term of this Agreement,
except that ordinary wear and tear shall not, under any circumstances, be deemed to give rise to an
Widespread Failure situation. In the event of an Widespread Failure, (a) Hitachi covenants that
Detectors not yet delivered to TomoTherapy will be upgraded, prior to delivery, to correct such
Widespread Failure, and (b) with respect to Detectors for which the warranty under subsection F of
Section 1.3 has expired, Hitachi will, at its own expense, provide to TomoTherapy such replacement
components for such Detectors or spare parts as may be required to eliminate the defect giving rise
to such Widespread Failure. TomoTherapy will perform any work relating to the installation or
other use of such replacement components at its own expense. With respect to this Section 1.4,
Hitachi shall assume responsibility for any defects or problems that otherwise fall within the
definition of “Widespread Failure” that are due to defects, flaws or omissions in any component of
the Detectors supplied to Hitachi by any of Hitachi’s vendors or suppliers.

2.0 REGULATION

2.1 Government Approvals. If applicable law in the sales territory of TomoTherapy requires
registration or listing of Detectors in order to offer them for sale or to install them within the
sales territory, such registration or listing shall be sole responsibility of TomoTherapy, unless
Hitachi, at its option, elects to make such registration or listing in its own name. If such
registration or listing is to be obtained or made by TomoTherapy, Hitachi shall cooperate and
assist TomoTherapy in its efforts, and the costs of such registration or listing shall be borne
exclusively by TomoTherapy.

2.2 Export Control Regulations. Neither Hitachi nor TomoTherapy shall dispose of any U.S.
products, know-how, technical data, documentation, or other products or materials furnished to it
pursuant to this Agreement to any party or in any manner which would constitute a violation of the
export control regulations of the United States now or hereafter in effect if the disposition was
made by a U.S. corporation, or a non-U.S. corporation subject to those regulations.

2.3 Safety, Performance or Regulatory Issues. Hitachi agrees to inform TomoTherapy
immediately of any safety, performance or regulatory issues relating to any Detectors, whether sold
to TomoTherapy, sold to a third party or in Hitachi’s possession.

2.4 Conformance to Law. Hitachi warrants and represents that it follows local Japanese law
with respect to its manufacturing, sales, and other business activities and that at this time,
Hitachi is aware of no law or regulation prohibiting the manufacture, sale, or export of the
Detectors to TomoTherapy.

2.5 Compliance with U.S. Foreign Corrupt Practices Act. Hitachi shall not, directly or
indirectly, in the name of or on behalf of, or for the benefit of TomoTherapy, offer, promise or
authorize to pay, or pay any compensation to, or give anything of value to, any official, agent or
employee of any government or governmental agency, or to any political party, or to any officer,
employee or agent thereof. Notwithstanding the provisions of Article 6.0 hereof, any breach of the
provisions of this Section 2.5 shall entitle TomoTherapy to terminate this Agreement effective
immediately upon notice, and with no further liability whatsoever, to Hitachi.

 

4

 

3.0 RELATIONSHIP BETWEEN THE PARTIES

3.1 Independent Purchaser Status. Hitachi is an independent contractor. Hitachi shall not be
considered an agent or legal representative of TomoTherapy for any purpose, and Hitachi agrees that none of the Hitachi Parties shall be, or be considered, an agent or employee of TomoTherapy.
Hitachi further agrees that none of the Hitachi Parties is granted, nor shall exercise, the right
or authority to assume or create any obligation or responsibility, including without limitation
contractual obligations and obligations based on warranties or guarantees, on behalf of or in the
name of TomoTherapy.

3.2 Controlled Entities. Hitachi’s obligations and responsibilities hereunder shall apply to
any person or entity owned or controlled by Hitachi.

3.3 TomoTherapy’s Sales Terms. TomoTherapy shall in no way be restricted in determining, at
its sole discretion, the prices, terms and conditions under which the Detectors are sold to its
customers.

4.0 INSURANCE, INDEMNIFICATION AND LIMITATION OF LIABILITY

4.1 Insurance. Hitachi shall secure and maintain in force continuously and without
interruption during the Term, the following insurance coverage: general liability insurance,
including product liability coverage, with per-occurrence limits of at least One Million Dollars
($1,000,000).

4.2 Indemnification.

	 	a.	 	Hitachi agrees to indemnify and hold harmless TomoTherapy from and
against any and all claims, losses, damages, liabilities, obligations, judgments,
settlements, costs and other expenses, of whatever form or nature, including,
without limitation, attorneys’ fees and other costs of legal defense, whether
direct or indirect, which TomoTherapy may sustain or incur from time to time as a
result of or related to any acts or omissions of Hitachi, including, without
limitation: (i) breach of any of the provisions of this Agreement or of a
representation or warranty made herein, (ii) a Widespread Failure, (iii) the
Detectors’ actual or alleged infringement of intellectual property rights,
including, without limitation, copyrights, trade secrets, trademarks, trade names,
patents and all other intellectual and industrial property rights of every kind and
nature throughout the world and however designated (the “Intellectual Property
Rights”), (iv) an actual or alleged failure of or defect in the Detectors resulting
in actual or alleged damages or injuries, (v) gross negligence or other tortious
conduct, (vi) representations or statements not specifically authorized by
TomoTherapy herein or otherwise in writing, or (vii) violation by Hitachi of any
applicable law, regulation or order. In case of (iii) or (iv) above, TomoTherapy
shall promptly inform of it to Hitachi and place the case under Hitachi’s control.

	 	b.	 	TomoTherapy agrees to indemnify and hold harmless Hitachi from and
against any and all claims, losses, damages, liabilities, obligation, judgments,
settlements, costs and other expenses, of whatever form or nature, including,
without limitation, attorneys’ fees and other costs of legal defense, whether
direct or indirect, which Hitachi may sustain or incur from time to time as a
result of or related to any acts or omissions of TomoTherapy, including, without
limitation, (i) breach of any of the provisions of this Agreement or of a
representation or warranty made herein, (ii) an actual or alleged failure of or
defect in the TomoTherapy product, excluding any defect in the Detectors, resulting
in actual or alleged damages or injuries, (iii) TomoTherapy’s Products’ actual or
alleged infringement of Intellectual Property Rights, excluding any infringement in
the Detectors, (iv) any modification of or addition to the Detectors not provided
or approved by Hitachi, (v) gross negligence or other tortuous conduct, (vi)
representations or statements made by TomoTherapy not specifically authorized by
Hitachi herein or otherwise in writing, or (vii) violation by TomoTherapy of any
applicable law, regulation or order.

4.3 Hitachi Limitation of Liability. IN NO EVENT SHALL HITACHI BE RESPONSIBLE OR LIABLE TO
TOMOTHERAPY FOR LOST PROFITS, OR LOST BUSINESS OPPORTUNITIES, OR INDIRECT, INCIDENTAL, SPECIAL,
PUNITIVE, OR CONSEQUENTIAL DAMAGES OF TOMOTHERAPY OR ANY OTHERS ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT OR ITS
TERMINATION.

 

5

 

4.4 TomoTherapy Limitation of Liability. UNDER NO CIRCUMSTANCES SHALL TOMOTHERAPY BE LIABLE
TO HITACHI FOR LOST PROFITS OR LOST BUSINESS OPPORTUNITIES, NOR SHALL TOMOTHERAPY BE SUBJECT TO ANY
CONSEQUENTIAL, SPECICAL, PUNITIVE, INCIDENTAL, INDIRECT OR CONTINGENT DAMAGES WHATSOEVER WITH
RESPECT TO CLAIMS MADE HEREUNDER.

5.0 CONFIDENTIAL INFORMATION

5.1 Hitachi and TomoTherapy each may be referred to separately as (i) the “Provider” in a
context in which the Party being referred to is disclosing, has disclosed, or will disclose
information, and (ii) the “Receiver” in a context in which the Party being referred to is
receiving, has received, or will receive information.

5.2 As used in this Agreement, “Confidential Information” means all information consisting of
or relating to the Provider’s: trade secrets, product designs, patents, patents pending or
contemplated and interpretation of patents, copyright and copyright pending or contemplated,
customer lists, product lines, methods of business operation, technical information, including
without limitation, software and computer programs, economic information data, specifications,
know-how, process information, methods of manufacture, formulas, structures, materials, components,
designs, patterns, prototypes, models, drawings, reports, notes, charts, graphs, distribution and
sale relating to the development and marketing of the Provider’s products and general business
operations..

5.3 Confidential Information includes without limitation all information that is able to be
disclosed, communicated, transferred, reproduced, represented, contained, retained, recorded, or
embodied orally, visually, electronically, digitally, in writing, or through any other medium or
means. In order to be included as Confidential Information hereunder, (i) information disclosed in
written or other tangible form must at the time of disclosure be identified as “Confidential”,
“Secret,” or “Proprietary” or bear a similar legend, and (ii) information disclosed in any other
form must be identified as Confidential Information hereunder in a written notice delivered by the
Provider to the Receiver within fourteen (14) days after the time of disclosure, provided that such
information shall be considered to be Confidential Information throughout at least such fourteen
(14) day period even if no such notice is ultimately delivered.

5.4 Notwithstanding the foregoing, Confidential Information does not include any information
disclosed by the Provider to the Receiver hereunder which the Receiver can convincingly demonstrate
through, among other means, the production of written records or other tangible materials (i) is,
at the time of such disclosure, already generally available to the public through no act or
omission in breach of this Agreement, (ii) becomes, subsequent to such disclosure, generally
available to the public through no act or omission in breach of this Agreement, (iii) is, at the
time of such disclosure, already in the Receiver’s possession through lawful means, and was not
obtained, directly or indirectly, from the Provider or from a third party under an obligation to
keep such information confidential, (iv) comes, subsequent to such disclosure, into the Receiver’s
possession through lawful means and is not obtained, directly or indirectly, from the Provider or
from a third party under an obligation to keep such information confidential, or (v) is, subsequent
to such disclosure, independently developed by employees of the Receiver who have not received such
information.

5.5 The Confidential Information shall (i) be the confidential property of the Provider and be
treated by the Receiver strictly and without exception as such, (ii) be securely retained and
protected by the Receiver without any loss or misplacement throughout the period in which it is in
the Receiver’s possession, (iii) not be disclosed, directly or indirectly, by the Receiver to any
party other than the Provider without the Provider’s prior written approval, and (iv) be used by
the Receiver only for the Permitted Purpose and not for any other purpose, reason, or application
without the Provider’s prior written approval.

 

6

 

5.6 The Receiver shall use at least the same degree of care to protect and keep confidential
the Provider’s Confidential Information as the Receiver uses to protect and keep confidential its
own Confidential Information. If the Receiver becomes legally compelled to disclose any of the
Provider’s Confidential Information, the Receiver shall immediately so notify the Provider in
writing so as to enable the Provider to respond to such compulsion. Each Party acknowledges that
its breach of this Agreement will cause irreparable harm to the other Party for which money damages
will not be a sufficient remedy. Accordingly, in the event of a breach of this Section 5 by either
Party, the other Party shall be entitled to equitable relief, including without limitation
injunctive relief, in addition to any other legal or equitable remedy to which such Party may be
entitled.

5.7 Upon the Provider’s request, the Receiver shall (i) immediately return to the Provider all
copies of the Provider’s Confidential Information which are in written or other tangible form,
except for that portion of such Confidential Information which consists of items (including without
limitation summaries, memoranda, correspondence, reports, notes, and other materials) that the
Receiver has generated itself based on such Confidential Information (the “Derivatives”), (ii)
immediately destroys all copies of such Confidential Information which are in any other form except
the Derivatives, and (iii) either retain and continue to protect and keep confidential the
Derivatives in compliance with this Agreement or immediately destroy all copies of the Derivatives,
as the Provider may elect. An officer of the Receiver shall prepare a written certification of
each such destruction and promptly deliver such certification to the Provider upon the completion
of each such destruction.

5.8 Period of Confidentiality. The parties agree to keep any Confidential Information, as
defined herein, confidential for the term of this Agreement and for a period of two (2) years after
the termination or expiration of the Agreement or any extension thereof. The previous statement
notwithstanding, the Receiver shall maintain the confidentiality of any information identified by
the Provider as a trade secret as long as the trade secret information remains a protectable trade
secret of the Provider.

6.0 TERM AND TERMINATION

6.1 Term. Unless terminated as provided in Section 6.2 hereof or by mutual written
consent, this Agreement shall continue in full force and effect for an initial term expiring [ * ]
years after the date hereof (the “Initial Term”), and thereafter may be renewed for successive one
(1) year terms (each a “Renewal Term”) by mutual agreement of the parties at least six (6) months
prior to the expiration of the Initial Term or any Renewal Term (collectively, the “Term”).

6.2 Termination. This Agreement may be terminated prior to expiration of the Initial Term or
any Renewal Term, as provided in Section 6.1 hereof, by prior notice to the other party as
follows:

A. By either party, immediately if the other party should fail to perform any of its
obligations hereunder and should fail to remedy such nonperformance within ninety (90) calendar
days after receiving written demand therefore;

B. By either party, effective immediately upon the liquidation, dissolution or termination of
the other party’s existence or business, or if that party becomes the subject of any voluntary or
involuntary bankruptcy, receivership or other insolvency proceedings or makes an assignment or
other arrangement for the benefit of its creditors,

C. By either party, effective immediately, if the other party should attempt to sell, assign,
delegate or transfer any of its rights and obligations under this Agreement without having obtained
the party’s prior written consent thereto except as specified in Section 7.5 herein.

 

7

 

6.3 Rights of Parties Upon Termination. The following provisions shall apply upon the
termination or nonrenewal of this Agreement:

A. Hitachi shall cease all manufacturing and other activities on behalf of TomoTherapy and
shall return to TomoTherapy and immediately cease all use of Confidential Information previously
furnished by TomoTherapy and then in Hitachi’s possession. TomoTherapy, too, shall return to
Hitachi and immediately cease all use of Confidential Information previously furnished by Hitachi
and then in TomoTherapy’s possession.

B. TomoTherapy shall purchase any and all outstanding Purchase Orders and all parts and
materials that Hitachi has already placed the order with suppliers for producing the Detectors
based on the Forecasts provided by TomoTherapy for the first three months beyond the Purchase
Orders except for the case this Agreement is terminated by TomoTherapy under Section 6.2.A above.

C. Upon termination by Hitachi for any reason other than TomoTherapy’s breach pursuant to
Section 6.2 hereof, TomoTherapy shall have the opportunity to do a Last Time Buy of the Detectors
from Hitachi. The Last Time Buy request shall be in the form of a Purchase Order that identifies
the order as the Last Time Buy, and specifies the quantity and delivery schedule of the Last Time
Buy Detectors. The parties shall discuss and agree on the quantity and delivery schedule of the
Last Time Buy, with the understanding that the quantity of Detectors available for purchase by
TomoTherapy in the Last Time Buy will at minimum be equivalent to the number of Detectors ordered
during the last calendar year of the Agreement. However, should Hitachi’s reason for termination
be due to Hitachi’s inability to source certain components of the Detectors such that continued
manufacture in the absence of other intervention would make it impossible for Hitachi to fulfill
the Last Time Buy request, the parties agree to the following:

	 	i.	 	Hitachi shall notify TomoTherapy as soon as
possible about the impending supply shortage. Hitachi and TomoTherapy
will work together to try and locate an alternate source for the
components.

	 	ii.	 	Hitachi agrees, with its commercial best effort
basis, to work with its current supplier to negotiate a similar Last Time
Buy provision to make a last purchase of the components from the supplier
in an amount equivalent to at least enough supply to provide TomoTherapy
with a number of detectors equivalent to the number of Detectors ordered
by TomoTherapy under this Agreement during the last six (6) calendar
months of the Agreement prior to termination.

D. The following provisions survive termination or nonrenewal of this Agreement for any
reason: Section 1.3F, Section 2.2, Section 2.3, Section 3.2, Article 4.0, Article 5.0, Section
6.3, Section 7.2, Section 7.4, Section 7.6, and Section 7.8.

E. In the event TomoTherapy terminates the Agreement as the result of Hitachi’s failure to
perform or breach pursuant to Section 6.2, or in the event that Hitachi terminates or fails to
renew the Agreement based upon a decision to cease manufacture of the Detectors, the parties shall
negotiate in good faith the possibility and terms and conditions of transfer of Hitachi’s
manufacturing Know-How and any other Hitachi Intellectual Property necessary for the manufacture of
the Detectors.

7.0 GENERAL PROVISIONS

7.1 Entire Agreement. This Agreement, including the Exhibits hereto, as it may be
amended from time to time, represents the entire agreement between the parties concerning the
subject matter hereof and supersedes all prior discussions, agreements and understandings of every
kind and nature between them. Except as otherwise expressly set forth herein, no modification of
this Agreement will be effective unless in writing and signed by both parties.

 

8

 

7.2 Notices. All notices under this Agreement shall be in writing and given by registered
mail, nationally recognized courier, facsimile, or by electronic transmission addressed to the
parties at the addresses set forth on the first page of this Agreement, or to such other address of
which either party may advise the other pursuant to this Section 7.2. Notices will be
deemed given when sent.

7.3 Force Majeure. Neither party shall be in default hereunder by reason of any failure
or delay in the performance of any of its obligations under this Agreement where such failure or
delay arises out of any cause beyond the reasonable control and without the fault or negligence of
non-performing party. Such causes shall include, without limitation, storms, floods, other acts of
nature, fires, explosions, riots, war, terrorism or civil disturbance, strikes or other labor
unrests, embargoes and other governmental actions or regulations which would prohibit either party
from ordering or furnishing Products or from performing any other aspects of its obligations
hereunder, delays in transportation, and liability to obtain necessary labor, supplies or
manufacturing facilities.

7.4 Severability. If any provision of this Agreement is held invalid by any tribunal in a
final nonappealable decision, such provision shall be deemed modified to eliminate the invalid element
and, as so modified, such provision shall be deemed a part of this Agreement as though originally
included. The remaining provisions of this Agreement shall not be affected by such modification.

7.5 Nonassignment. This Agreement shall be binding upon and inure to the benefit of the
successors and assigns of the business interests of the parties and may be assigned by either party
only to the acquirer of substantially all of that party’s assets in conjunction with such an
acquisition, or with the written consent of the other party.

7.6 Conciliation and Arbitration. Prior to commencing any legal action, all disputes
arising between the parties concerning (a) the rights and obligations of the parties under this Agreement
or (b) any damages suffered by a party arising from a claimed breach by the other party shall be
brought before a conciliation committee of executives representing both parties. The committee
shall attempt to work out a recommendation for settlement of the dispute and transmit such
recommendation to both parties for due consideration not more than 60 days after one party gives
the other party notice that a dispute exists. Any dispute that cannot be settled amicably by
conciliation within the 60-day period shall be finally heard, settled, and decided under the Rules
of the American Arbitration Association in effect as of the Effective Date by three arbitrators
(one of whom may not be a citizen of the country of either party) appointed in accordance with such
Rules, and Wisconsin law shall govern the interpretation of this Agreement. Service of any matters
in reference to such arbitration shall be given in the manner described in Section 7.2 above. Such
arbitration shall be conducted in English using the English language text of this Agreement, and
the arbitrators shall have a demonstrated fluency in both written and spoken English. The
arbitration shall be held in New York, New York state, unless the parties shall otherwise mutually
agree. The award in such arbitration shall be final and enforceable in any court of competent
jurisdiction.

7.7 Waiver. Both parties agree that the failure of either party at any time to require
performance by the other party of any of the provisions herein shall not operate as a waiver of the
right of the party to request strict performance of the same or like provisions, or any other
provisions hereof, at a later time.

7.8 No Third-Party Beneficiaries. Nothing herein, express or implied, is intended or shall
be construed to confer upon or give to any person, other than the parties hereto and their
successors or permitted assigns, any rights or remedies under or by reason of this Agreement.

7.9 Language. The English language version of this Agreement shall at all times govern and
control the interpretation and enforcement of this Agreement notwithstanding the translation of
this Agreement into any other language.

7.10 Currency. “Yen” shall mean the legal currency of Japan. All
amounts referred to in this Agreement and the Exhibits hereto shall be paid in such currency unless
specifically expressed otherwise.

 

9

 

7.11 Recitals. The recitals hereto are an integral part of this Agreement and are incorporated
herein by reference.

7.12 Headings. Any headings used herein are for convenience in reference only and are not
a part of this Agreement, nor shall they in any way affect the interpretation hereof.

7.13 Counterparts. This Agreement may be executed simultaneously in several
counterparts, including facsimile copies, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, TomoTherapy and Hitachi have caused this instrument to be executed by their
duly authorized employees, as of the date first above written.

	 	 	 	 	 	 	 
	TOMOTHERAPY INCORPORATED	 	HITACHI MEDICAL CORPORATION
	 
	 	 	 	 	 	 
	By:

	 	/Steve Books/
	 	By:
	 	/Kazuyoshi Miki/
	 

	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	Name:

	 	Steve Books
	 	Name:
	 	Kazuyoshi Miki
	 

	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	Its:

	 	Chief Operating Officer
	 	Its:
	 	Senior Vice President and Executive Officer
	 

	 	 
	 	 	 	 
	 
	 	 	 	 	 	 
	Date:

	 	June 19, 2008	 	Date:	 	June 25, 2008
	 

	 	 
	 	 	 	 

 

10

 

APPENDIX A

Procurement Specification for the Detectors

[ * ]

 

C-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00144-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00144-of-00352.parquet"}]]